Blogs

Life-saving pharmaceutical products must reach patients in a condition that supports safety, stability, and performance. Packaging serves as the primary barrier against contamination, moisture, and gas ingress throughout distribution and storage. Container Closure Integrity (CCI) testing allows manufacturers to evaluate whether this barrier remains intact over time. As drug formulations become more complex and packaging formats continue to evolve, testing approaches have also progressed. Non-destructive CCI testing methods are increasingly used because they examine package integrity without damaging the container. These methods provide reliable insight during development, validation, and routine manufacturing while preserving valuable samples.

Limitations of Destructive Testing

Destructive CCI testing methods typically involve dye ingress, microbial challenge, or physical manipulation that permanently damages the test sample. Once tested, the package cannot be returned to the supply chain. This limits sample sizes and reduces confidence when evaluating high-value or limited-availability products such as biologics and injectable drugs.

Another drawback is variability. Many destructive techniques rely on visual interpretation, which can differ between operators. Sensitivity may also be limited, making it difficult to detect very small leak paths that still allow contamination over time. These methods are often unsuitable for in-line or high-frequency testing, creating gaps in quality monitoring. As product complexity increases, these constraints make destructive testing less practical for modern pharmaceutical operations.

What are Non-Destructive Testing Methods?

Non-destructive methods are testing techniques used to evaluate a product or package without causing damage or altering its structure, function, or usability. In pharmaceutical packaging, non-destructive methods assess container closure integrity by detecting leaks or defects while keeping the container fully intact. These techniques rely on measurable physical signals—such as pressure changes or electrical conductivity—rather than visual inspection. As a result, tested samples can be reused for further evaluation, stability studies, or release activities while still providing reliable, repeatable information about package performance.

Common non-destructive methods used in pharmaceutical CCIT include:

Vacuum decay leak testing is widely used for both rigid and flexible packaging. In this method, the package is placed inside a test chamber where a vacuum is applied. Any leak allows air to escape from the package, creating a measurable change in pressure. This approach is highly sensitive and works well for vials, blister packs, pouches, and combination products.

High Voltage Leak Detection (HVLD) is another non-destructive method used primarily for liquid-filled parenteral products. It applies a high-voltage signal across the container. When a defect is present, changes in electrical conductivity indicate the location of a leak. HVLD is suitable for prefilled syringes, ampoules, and vials containing conductive liquids.

Both methods support deterministic testing by delivering measurable data and clear pass/fail outcomes. Their adaptability across packaging formats makes them suitable for various stages of pharmaceutical manufacturing.

Benefits of Non-Destructive Testing

• Identifies very small leak paths that may not be detected by visual or destructive methods
• Preserves package integrity, allowing samples to remain usable after testing
• Supports repeat testing of the same units during stability and lifecycle studies
• Delivers objective, quantitative results with clear acceptance criteria
• Reduces product waste and material loss, especially for high-value products
• Integrates well with automated and high-throughput manufacturing environments
• Improves consistency and repeatability across testing programs
• Applies to a wide range of pharmaceutical packaging formats
• Strengthens confidence in package performance throughout storage and distribution

Non-destructive CCI testing has become a widely adopted approach for evaluating packaging used for life-saving pharmaceutical products. By overcoming the challenges associated with destructive techniques, methods such as vacuum decay and high voltage leak detection offer accurate, repeatable insight into container integrity. These technologies allow manufacturers to examine packaging performance across development and production while preserving valuable samples. Through routine application, non-destructive CCI testing supports consistent package quality, reduced material waste, and reliable protection for products intended to support patient health.

Life science packaging has evolved rapidly as pharmaceuticals, biologics, and medical devices become more sensitive to environmental exposure. Advances in drug delivery systems, combination products, and sterile manufacturing have increased expectations for package performance across the product lifecycle. Even microscopic defects can allow the ingress of gases, moisture, or microorganisms, influencing product quality long before it reaches the patient. As a result, leak detection technologies are increasingly influencing how packaging systems are designed, evaluated, and monitored, setting new benchmarks for quality assurance and regulatory confidence.

Why Has Leak Detection Become a Strategic Priority?

Life science products often encounter multiple stress points, including fill-finish, transportation, cold-chain storage, and extended shelf life. Packaging must withstand these conditions while maintaining a stable internal environment. Regulatory agencies now expect manufacturers to demonstrate package integrity using deterministic and quantitative approaches rather than probabilistic methods.

Another driver is the growing use of high-value therapies such as biologics, cell and gene therapies, and implantable medical devices. These products demand tighter control over oxygen and moisture ingress, as even minimal exposure can influence performance. Leak detection supports risk-based quality strategies by identifying defects early, reducing batch failures, and supporting consistent manufacturing outcomes.

Sustainability efforts are also reshaping packaging formats, with thinner materials and innovative designs entering the market. These changes introduce new integrity challenges that traditional inspection techniques may not address effectively. Modern leak detection methods offer higher sensitivity and repeatability, making them well suited for validating emerging packaging formats without compromising production efficiency.

Core Leak Detection Technologies Driving Future

Vacuum Decay Technology

Vacuum Decay leak testing is a deterministic, non-destructive method that evaluates package integrity by measuring changes in pressure within a sealed test chamber. During testing, the package is placed inside the chamber, and a controlled vacuum is applied. If a defect or leak path is present, air or gas escapes from the package into the chamber, producing a measurable pressure change. Vacuum Decay can be configured for rigid, semi-rigid, and flexible packaging, making it suitable for trays, pouches, blisters, and device packages. In shelf-life studies, the non-destructive nature of the method supports repeated testing of the same package population at multiple aging intervals, enabling trend analysis of seal performance over time.

HVLD Technology

High Voltage Leak Detection (HVLD) is a non-destructive method for testing container closure integrity in liquid-filled pharmaceutical and parenteral products, including low-conductivity formulations like sterile water or protein solutions. It uses very low electrical current to detect leaks without affecting the product or generating ozone. The method works on the principle that an intact container resists current flow, while any micro-leak or fracture allows electricity to pass through the defect. Unlike other leak detection methods, MicroCurrent HVLD identifies breaches without requiring mass to move through the leak site. HVLD is commonly used for glass and polymer containers with elastomeric closures, including vials, ampoules, prefilled syringes, and fluid-filled medical device packaging. 

Helium Leak Detection

Helium leak detection uses helium gas as a tracer to identify and measure very small leaks in sealed packages. In helium mass spectrometry, helium is introduced into or around the package under controlled conditions. Any helium escaping through a defect is captured and quantified by a mass spectrometer, producing a precise leak rate measurement. Because helium atoms are small and inert, this method offers high sensitivity and repeatability. Helium testing is commonly used during method development, package design evaluation, and aging studies to establish detection limits and correlate measured leak rates with allowable leakage thresholds.

Leak detection technologies are reshaping how life science packaging is evaluated and maintained throughout development and commercialization. As products become more complex and packaging designs continue to evolve, deterministic and sensitive testing methods provide manufacturers with greater visibility into package performance. By supporting data-driven decisions, regulatory compliance, and product protection, modern leak detection approaches are setting the direction for the future of life science packaging quality.

Pharmaceutical packaging is designed to maintain a controlled internal environment from the point of filling through storage, transportation, and use. Any unintended opening in a sealed system can allow gases, moisture, or external contaminants to enter the package. These pathways may be extremely small and not visible during visual inspection. As pharmaceutical manufacturers work with a wide range of rigid and flexible packaging formats, non-destructive leak detection technologies have become widely adopted. Vacuum decay testing offers a practical and repeatable approach for evaluating package integrity across many pharmaceutical applications.

What is Vacuum Decay Testing and How it Works?

Vacuum Decay is a non-destructive Container Closure Integrity Testing (CCIT) method used to evaluate package integrity by identifying leak pathways. When compared with manual inspection and other non-deterministic techniques, vacuum decay delivers quantitative, deterministic, and repeatable results for package evaluation. The technology supports a broad range of packaging formats, including filled and sealed rigid, semi-rigid, and flexible packages manufactured from porous or non-porous materials.

During testing, packages are placed inside a properly fitted test chamber connected to an external vacuum source. The vacuum levels are continuously monitored to identify any variations from a pre-determined targeted vacuum level. A defect in the package will cause air to escape from the package into the test chamber. On the other hand, packages without any defect hold in the air, maintaining constant chamber vacuum level. Vacuum Decay technology has been proven over years to be one of the most practical and sensitive vacuum-based leak detection solutions.

Applications of Vacuum Decay in Rigid and Flexible Pharmaceutical Packaging

Vacuum decay testing is widely used in the pharmaceutical industry to evaluate package integrity without damaging the product. Its versatility allows application across both rigid and flexible packaging formats.

1. Rigid Pharmaceutical Containers

Vacuum decay is suitable for vials, ampoules, prefilled syringes, cartridges, and bottles. These packages may develop small leaks due to stopper misalignment, crimping variations, or handling during manufacturing. Vacuum decay detects micro-leaks, helping maintain quality and safety without breaking or destroying the container.

2. Flexible Packaging Formats

Flexible packaging, such as IV bags, pouches, sachets, and blister packs, presents unique challenges due to low headspace and material deformation. Vacuum decay systems account for these factors, allowing reliable detection of leaks even in soft, pliable packages where visual or dye-based inspections may be insufficient.

3. Filled Product Testing

The method supports testing of filled packages containing liquids, powders, or lyophilized products. Non-destructive testing ensures that the product remains usable after evaluation, enabling development studies, stability checks, and routine quality monitoring.

4. Packaging Development and Design Evaluation

During development, vacuum decay testing helps assess different materials, seal types, and packaging designs. It allows teams to compare configurations and identify which options maintain integrity under expected handling and storage conditions.

5. Routine Quality Monitoring

Vacuum decay supports in-process checks and lot release activities. Its repeatable, quantitative results allow manufacturers to monitor package performance consistently across production batches.

6. Compatibility with Various Materials

The technology accommodates both porous and non-porous materials, including plastics, glass, and laminated films, making it suitable for diverse packaging applications throughout the pharmaceutical lifecycle.

Vacuum decay testing provides a versatile, non-destructive approach for pharmaceutical package testing, supporting the evaluation of integrity in rigid and flexible packaging systems. By detecting small leaks through controlled vacuum monitoring, this method accommodates a wide range of container types, materials, and fill conditions. Its adaptability makes it suitable for development studies, manufacturing oversight, and long-term package evaluation. As pharmaceutical packaging continues to evolve, vacuum decay remains a widely adopted pharmaceutical package testing approach that aligns with modern quality expectations and supports confidence in sealed packaging systems across diverse applications.

Drug delivery systems have undergone significant transformation over the past decade. The industry has moved beyond conventional vials and ampoules toward prefilled syringes, autoinjectors, wearable injectors, inhalers, and combination products that integrate drug, device, and packaging into a single therapeutic platform. These formats are designed to enhance dosing accuracy, patient convenience, and treatment adherence. As delivery systems become more complex, packaging performance expectations have also intensified. Container Closure Integrity Testing (CCIT) has evolved alongside these changes, offering science-based methods to evaluate whether packaging systems maintain a sterile barrier throughout their lifecycle.

Why CCIT Matters More Than Ever?

Advanced drug delivery systems often involve biologics, cell and gene therapies, and highly potent formulations that display sensitivity to oxygen, moisture, and microbial ingress. Many of these products are manufactured in low volumes, stored under controlled temperatures, and distributed globally. The packaging must tolerate mechanical stress, thermal cycling, and extended storage without compromising closure integrity.

Unlike traditional containers, modern delivery systems frequently include multiple seals, elastomeric components, adhesive bonds, and interfaces between materials with different physical properties. Each interface introduces potential pathways for leakage. CCIT provides a structured approach to evaluate these risks by generating quantitative, repeatable data on package integrity. Regulatory expectations, reflected in guidance such as USP <1207>, increasingly emphasize deterministic test methods that can demonstrate package performance with traceable evidence rather than subjective interpretation.

Limitations of Traditional Integrity Testing

Historically, integrity evaluation relied heavily on probabilistic methods such as dye ingress, bubble emission, and microbial challenge testing. While these techniques have long been used, they present limitations when applied to advanced delivery systems. Many are destructive, making them unsuitable for high-value products or small batch sizes. Others depend on operator judgment, which introduces variability and limits reproducibility.

In addition, traditional methods often struggle to detect microleaks that fall below visual or microbial thresholds yet still allow long-term ingress of gases or moisture. For combination products with complex geometries, these methods may fail to adequately challenge all potential leak paths. As delivery systems become more intricate, reliance on legacy approaches can leave gaps in package evaluation strategies.

Advanced CCIT Technologies Powering Modern Drug Delivery

Vacuum Decay technology: Vacuum Decay technology is the most practical and sensitive vacuum-based leak test method. It detects leaks by monitoring pressure changes within a sealed test chamber containing the package under evaluation. After a controlled vacuum is applied, any loss of pressure indicates the presence of a leak, allowing quantitative measurement of package integrity. This method is suitable for both rigid and flexible packaging formats and can be configured for a wide range of advanced drug delivery systems, including prefilled syringes, cartridges, blister packs. 

HVLD technology: HVLD is a non-destructive highly sensitive technology for container closure integrity for wide range of liquid filled parenteral products. identifies leaks by applying a low electrical potential across a sealed container filled with conductive liquid. When a breach exists, even at a microscopic level, current passes through the leak path and is detected by the system. This technology is proven to be a highly sensitive leak detection method for various types of liquid-filled packaging including, but not limited to pre-filled syringes, vials, cartridges and ampoules.

Helium Leak Detection: Helium leak detection is a deterministic testing method used to identify and measure leaks in sealed packages by using helium gas as a tracer. During testing, helium is introduced into or around the package, and any escaping gas is measured using a highly sensitive detector. These techniques are widely applied during feasibility studies, method development, and validation to define detection limits and establish correlations with Maximum Allowable Leakage Limits (MALL). The high sensitivity of helium testing supports detailed evaluation of package performance during design qualification and comparative studies.

As drug delivery systems continue to advance, packaging integrity assessment must keep pace with increased complexity and heightened performance expectations. CCIT has transitioned from a compliance-driven activity to a data-driven discipline that supports product understanding, risk management, and regulatory alignment. By adopting deterministic technologies, manufacturers can evaluate package integrity with greater confidence across diverse delivery platforms. In an environment shaped by innovation in therapeutics and devices, CCIT provides a structured framework for assessing whether packaging systems perform as intended throughout development, distribution, and patient use.

Container Closure Integrity Testing (CCIT) is used to confirm that a sealed package resists the entry or escape of gases, moisture, and microorganisms across distribution and storage. Packaging systems encounter multiple sources of stress during filling, handling, shipping, and long-term storage. A well-structured CCIT method allows manufacturers to verify seal quality using measurable data rather than visual judgment alone. Because each container format responds differently to test conditions, CCIT cannot rely on a universal setup. Method development and validation establish defined operating ranges, detection capability, and performance limits that remain consistent across production and stability programs.

Why Method Development & Validation Matters for CCIT?

Every container system presents a unique combination of material structure, closure design, fill volume, and internal conditions. These variables influence how a leak presents itself during testing. If a testing method is applied without prior development work, it may fail to identify small defects or may generate variable results that weaken confidence in inspection outcomes.

Method validation provides documented evidence that a selected CCIT approach functions within specific limits and delivers dependable output. It confirms that the test can distinguish intact containers from those with known defects under controlled conditions. From a regulatory standpoint, validation supports data traceability and inspection readiness. From an operational standpoint, it allows manufacturing teams to apply a testing process that has been demonstrated to function with consistency across instruments, operators, and time. Together, development and validation establish a structured pathway for dependable seal verification.

Steps to Develop and Validate a CCIT Method

Developing and validating a robust method for Container Closure Integrity Testing requires a structured, science-based approach. PTI’s method development process typically includes the following stages:

1. Feasibility Study

The process begins by evaluating the suitability of different CCI technologies for the selected container system. This includes reviewing packaging design, material composition, headspace conditions, and product type such as liquid, lyophilized, or gas-filled formats. During this phase, PTI assesses whether Vacuum Decay, Helium Leak Detection, or High Voltage Leak Detection (HVLD) aligns best with the required detection range and regulatory expectations. The outcome of this study supports technology selection before formal testing begins.

2. Baseline Testing

After technology selection, baseline measurements are generated using known intact samples and intentionally defective units. These results establish initial performance ranges, leak rate thresholds, and system sensitivity. Baseline data serves as a reference point for all future optimization and validation work.

3. Method Optimization

At this stage, test parameters such as test pressure, dwell time, vacuum settings, scan speed, and data acquisition rates are adjusted through repeated trials. The objective is to achieve stable output with low variability across multiple sample batches. PTI engineers use accumulated test data to determine operating settings that produce consistent and highly sensitive readings without overstressing the container.

4. Validation and Robustness Studies

Once optimization is complete, the method enters formal validation in alignment with USP <1207> and related guidance. Validation activities typically include:

• Accuracy, which confirms detection of true leaks.
• Precision, which evaluates repeatability and reproducibility.
• Specificity, which distinguishes actual defects from non-relevant variables.
• Detection limit, which defines the smallest measurable leak rate.
• Robustness, which confirms method performance under varied test conditions.

Data from these studies confirms that the method functions within defined limits across operators, instruments, and testing days.

5. Documentation and Training

After validation, comprehensive documentation is prepared covering procedures, test parameters, acceptance limits, and study outcomes. These records support regulatory submissions and internal quality systems. Operator training follows to confirm uniform method execution during routine testing, shift changes, and site expansions.

6. Continuous Monitoring and Revalidation

A validated method is maintained through scheduled performance checks and periodic system verification. Changes in packaging components, sealing equipment, or storage exposures may trigger reassessment. PTI provides continued support for revalidation and method refinement to maintain long-term testing reliability as production conditions evolve.

Developing and validating a CCIT method follows a structured pathway built on package understanding, technology selection, test optimization, and documented verification. Through feasibility studies, controlled optimization, formal validation, and ongoing monitoring, manufacturers establish a testing framework that supports consistent integrity inspection across development, manufacturing, and stability programs.

Biologic medicines originate from living systems, making them exceptionally sensitive to environmental conditions. Throughout clinical trials, these products move through multiple stages—filling, inspection, transportation, cold storage, and frequent manual handling—each introducing potential stress to the package. Even a microscopic seal defect can permit oxygen, moisture, or other contaminants to enter, potentially altering the formulation before it reaches the patient. Because clinical outcomes depend on consistent performance across every trial batch, packaging reliability is scrutinized at every step of development. Container Closure Integrity Testing (CCIT) provides a rigorous, science-based way to verify that containers maintain their protective barrier throughout the entire clinical supply chain.

Why Biologic Stability is so Critical in Clinical Trials?

Biologic products such as vaccines, monoclonal antibodies, and cell-based therapies contain complex molecular structures that respond poorly to exposure outside controlled ranges. Temperature shifts, oxidation, and moisture ingress can trigger protein unfolding, aggregation, or potency loss. During clinical studies, stability data supports storage conditions, expiration dating, dosing strategy, and safety monitoring. If environmental exposure occurs because of seal weakness, the study material administered to subjects may no longer match the quality profile defined during formulation development. This can influence safety findings, blur dose–response relationships and create uncertainty in trial data interpretation. For these reasons, biologic stability management during trials extends well beyond formulation science and into packaging performance verification.

What is Container Closure Integrity Testing (CCIT)?

Container Closure Integrity Testing refers to deterministic inspection methods used to confirm whether a sealed package resists the passage of gases, liquids, or microorganisms. Unlike visual inspection, CCIT detects leakage paths that cannot be seen with the naked eye. These techniques generate quantitative measurements rather than subjective judgments. Common CCIT technologies include vacuum decay systems that track pressure changes, helium-based methods that measure tracer gas movement, and voltage-based detection for liquid-filled containers.

CCIT should be applied during packaging development, process qualification, stability studies, and routine production monitoring. During development, it supports evaluation of container materials, stopper designs, seal geometry, and crimping parameters. During qualification, it confirms that sealing processes generate repeatable outcomes across production campaigns. During stability programs, it verifies that containers continue to isolate the biologic from environmental exposure over time. Together, these applications provide consistent data on seal performance across the product lifecycle.

The Role of CCI Technologies in Clinical Trials

Different container formats used in biologic trials demand testing methods that align with both the package design and the physical state of the product. Two widely applied methods in this space are Vacuum Decay and High Voltage Leak Detection (HVLD).

Vacuum Decay Technology

Vacuum Decay is a non-destructive test method widely used for detecting leaks in containers with headspace, including vials, syringes, and flexible packages. During testing, the sealed container is placed inside a chamber where a controlled vacuum is applied. Any change in pressure within the chamber indicates gas movement caused by a package defect. This method provides quantitative, repeatable data and does not require tracer gases, making it suitable for routine clinical supply inspection. Vacuum Decay is often applied during packaging development, process verification, and stability programs to confirm that sealing systems continue to resist environmental exposure across storage and distribution conditions.

High Voltage Leak Detection (HVLD)

High Voltage Leak Detection is designed for liquid-filled containers such as injectable vials and pre-filled syringes commonly used in biologic trials. This method applies an electrical field around the sealed container while monitoring current flow. If a defect is present, the electrical resistance changes as the conductive liquid interacts with the surrounding environment. HVLD is highly effective for identifying pinholes, microcracks, and seal voids without opening or damaging the package. It supports both off-line inspection and in-line monitoring, allowing manufacturers to observe sealing consistency during clinical supply production and reduce the chances of compromised units reaching trial sites.

Biologic stability during clinical trials depends on the uninterrupted performance of the container closure system across multiple handling and storage steps. Container Closure Integrity Testing supplies data-driven confirmation that packages remain sealed against environmental exposure from fill–finish through patient administration. By supporting package design studies, sealing process validation, transport simulation, and long-term stability programs, CCIT strengthens confidence in clinical trial supply quality. As biologic pipelines expand and delivery formats become more advanced, CCIT continues to provide a dependable scientific framework for maintaining packaging performance throughout clinical development.